kabutan

Astellas Pharma, The Current Fiscal Year Net Income Revised Downward to an Unexpected 18% Decrease

Fri Jan 24, 2025 4:00 pm JST Revision

4503 Astellas Pharma Inc. 【IFRS】

Guidance Update Report

Astellas Pharma Inc. <4503> [TSE Prime] announced a performance revision after the market closed on January 24th (16:00). The consolidated net income for the fiscal year ending March 2025 has decreased 72.0%, from the previous forecast of 50 billion yen to 14 billion yen (compared to 17 billion yen in the previous period). This changes the outlook from an anticipated profit increase to a projection of a 17.9% decrease in profit.

Based on the downwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (2H) consolidated net income/loss has been revised downward from an expected loss of 23.5 billion yen to a loss of 59.5 billion yen (compared to a loss of 18.7 billion yen in the same period of the previous year), indicating an expansion in the loss margin.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 Prev 864,379 -13,710 -19,042 -23,511 -13.1 37 Oct 30, 2024 IFRS
Oct - Mar, 2024 New 964,379 -82,710 -88,042 -59,511 -33.2 37 Jan 24, 2025 IFRS
Revision Rate +11.6% -503.3% -362.4% -153.1% -153.2%

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Prev 1,800,000 80,000 70,000 50,000 27.9 74 Oct 30, 2024 IFRS
Mar, 2025 New 1,900,000 11,000 1,000 14,000 7.8 74 Jan 24, 2025 IFRS
Revision Rate +5.6% -86.3% -98.6% -72.0% -72.0%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 836,534 -29,638 -31,349 -18,765 -10.5 35 Apr 25, 2024 IFRS
Oct - Mar, 2024 Guidance 964,379 -82,710 -88,042 -59,511 -33.2 37 Jan 24, 2025 IFRS
YoY +15.3% -179.1% -180.8% -217.1% -217.5%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 1,518,619 133,029 132,361 98,714 54.2 60 Apr 27, 2023 IFRS
Mar, 2024 1,603,672 25,518 24,969 17,045 9.5 70 Apr 25, 2024 IFRS
Mar, 2025 Guidance 1,900,000 11,000 1,000 14,000 7.8 74 Jan 24, 2025 IFRS
YoY +18.5% -56.9% -96.0% -17.9% -17.8%

Related Articles